Dr. Frederick Sancilio reports

LOBE SCIENCES LTD. ENGAGES MASSIVE INTELLIGENCE PTY LTD FOR INVESTOR RELATIONS AND CORPORATE COMMUNICATIONS SERVICES

Lobe Sciences Ltd. has engaged Massive Intelligence Pty. Ltd. to provide investor relations and corporate communications services.

Pursuant to an engagement letter dated April 15, 2026, the company has retained Massive Intelligence for an initial term of three months, commencing April 15, 2026, with the option to renew for a further six months subject to written agreement of the parties.

Massive Intelligence will provide investor relations and promotional services on behalf of the company, including the development of investor materials and corporate communications content, distributed via social media channels, e-mail and press releases. The company will pay Massive Intelligence a fixed monthly cash retainer over the course of the engagement. During the initial three-month term, this equates to a total of $11,800 (U.S.), paid in monthly instalments. If the agreement is renewed, the company will commit an additional $31,500 (U.S.) over the subsequent six-month period, also paid monthly. No securities of the company will be issued in connection with this engagement

Massive Intelligence is arm's length to Lobe Sciences. To the company's knowledge, neither Massive Intelligence nor any of its directors, officers or employees currently holds any securities of the company or has any right or intent to acquire such securities, other than securities that may be purchased through the open market. Massive Intelligence is not a registered dealer or adviser under applicable securities legislation.

Massive Intelligence is based in Melbourne, Australia. The lead representative for Massive Intelligence is Angus Kennelly, managing director, who can be reached at angus@massiveintelligence.com.au or +61 413 541 301.

About Lobe Sciences Ltd.

Lobe Sciences is a clinical-stage biopharmaceutical company advancing programs in diseases with unmet medical needs. The company is pursuing strategic development through its subsidiaries, including a majority interest in Cynaptec Pharmaceuticals Inc. and wholly owned subsidiary Applied Lipid Technologies Inc. (formerly Altemia Inc.).

About Cynaptec Pharmaceuticals Inc.

Cynaptec is a biopharmaceutical company dedicated to developing innovative therapies for neurological and psychiatric disorders. Cynaptec's initial development program is focused on the use of its proprietary L-130 (psilocin mucate) compound for treatment of the significant unmet medical needs of patients with Chronic Cluster Headache, with an additional preliminary proof-of-concept to assess potential utility for substance use disorders. Cynaptec is 64 per cent owned by Lobe.

About L-130 (psilocin mucate)

L-130 is a novel, patented, oral, stable analog of psilocin, the active metabolite of the pro-drug psilocybin, designed to enhance bioavailability and therapeutic efficacy, which has been identified as having therapeutic potential in a variety of neurological conditions. Whereas conventional psilocin is an unstable compound that has been challenging for the industry to develop as a stand-alone pharmaceutical, L-130's stability and bioavailability profile, and associated safety and efficacy signals, suggest the potential for prescription drug development in a variety of neurological and psychiatric indications.

About Applied Lipid Technologies, Inc.

Applied Lipid Technologies, a wholly owned subsidiary of Lobe Sciences, is a biopharmaceutical company focused on developing novel lipid therapeutics to address unmet medical needs. The company is advancing S-100, a complex lipid, self-emulsifying oral dosage formulation, as a drug candidate for the treatment of sickle cell disease. Patents covering the formulation have been issued, with additional applications pending. A phase 2a clinical program may commence in early 2027. Applied Lipid Technologies was previously known as Altemia Inc.

We seek Safe Harbor.